Despite recent progress in antithrombotic therapy, there is still an unmet medical need for safe and orally available anticoagulants. The coagulation enzyme Factor Xa (FXa) is a particularly promising anticoagulant target. BAY 59-7939 (5), a highly potent and selective, demonstrated direct FXa inhibitor. Compound 5 is currently under clinical development for the prevention and treatment of thromboembolic diseases.
Model Description
This biologic model of Factor Xa in Complex with Small Molecule Inhibitor is 3D printed in full-color sandstone.
Select the desired material finish and size below. Matte finish applies a UV protective, semi-glossy coating.
